Interaction of the G182C polymorphism in the APOA5 gene and fasting plasma glucose on plasma triglycerides in Type 2 diabetic subjects

Diabetic Medicine

Volumn 22, Issue 12, 2005, Pages 1690-1695

  Jiang, Y D ^a   Yen, C J ^a   Chou, W L ^a   Kuo, S S ^a   Lee, K C ^a   Chiu, K C ^b   Chuang, Lee Ming ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Apolipoprotein AV; Hypertriglyceridaemia; Non synonymous substitution; Single nucleotide polymorphism; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A5; GLUCOSE; GUANINE NUCLEOTIDE; PYRIMIDINE NUCLEOTIDE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIABETES CONTROL; DYSLIPIDEMIA; FEMALE; GENE INTERACTION; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; SAMPLE SIZE; SEX RATIO; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEINS; APOLIPOPROTEINS A; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; TAIWAN; TRIGLYCERIDES;

EID: 30044432873     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01715.x     Document Type: Article

References (27)

1. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care 1991; 14: 839-855.
2. Syvanne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997; 350: SI20-SI23.
3. Chen YD, Coulston AM, Zhou MY, Hollenbeck CB, Reaven GM. Why do low-fat high-carbohydrate diets accentuate postprandial lipemia in patients with NIDDM? Diabetes Care 1995; 18: 10-16.
4. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
5. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol 1995; 6: 209-214.
6. Malloy MJ, Kane JP. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med 2001; 47: 111-136.
7. Tanne D, Koren-Morag N, Graff E, Goldbourt U. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 2001; 104: 2892-2897.
8. Nyman JA, Martinson MS, Nelson D, Nugent S, Collins D, Wittes J et al. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial. Arch Intern Med 2002; 162: 177-182.
9. Ericsson C, Hamsten A, Nilsson J, Grip L, Svane B, Faire UD. Angiographic assessment of effects of bezaf ibrate on progression of coronary artery disease in young male post-infarction patients. Lancet 1996; 347: 849-853.
10. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. New Engl J Med 1999; 341: 410-418.
11. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604.
12. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 160-178.
13. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003; 26: S83-S86.
14. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? J Am Med Assoc 1990; 263: 2893-2898.
15. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001; 294: 169-173.
16. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004; 279: 27941-27947.
17. Nabika T, Nasreen S, Kobayashi S, Masuda J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis 2002; 165: 201-204.
18. Endo K, Yanagi H, Araki J, Hirano C, Yamakawa-Kobayashi K, Tomura S. Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet 2002; 111: 570-572.
19. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002; 11: 3039-3046.
20. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002; 11: 3031-3038.
21. Ribalta J, Figuera L, Fernandez-Ballart J, Vilella E, Castro Cabezas M, Masana L et al. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem 2002; 48: 1597-1600.
22. Martin S, Nicaud V, Humphries SE, Talmud PJ. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta 2003; 1637: 217-225.
23. Baum L, Tomlinson B. Thomas GN. APOA5-1131T > C polymorphism is associated with triglyceride levels in Chinese men. Clin Genet 2003; 63: 377-379.
24. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 2003; 12: 2533-2539.
25. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1195.
26. Frank P, Marcel YL. Apolipoprotein A-I: structure-function relationships. J Lipid Res 2000; 41: 853-872.
27. Szalai C, Keszei M, Duba J, Prohaszka Z, Kozma GT, Csaszar A et al. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis 2004; 173: 109-114.